First Analysis
http://www.firstanalysis.com/index.asp?PID=16First Analysis is an investment organization specializing in private equity, venture capital, investment banking, and equity research. The sectors in the firm’s coverage universe include outsourced services, IT products and services, and chemistry-enabled businesses. First Analysis was founded in 1981.
View Older Stories
-
Form D First Analysis Fund XIV
-
Form D First Analysis Fund XIV,
-
Madrigal Pharma (MDGL) Presents Phase 3 MAESTRO-NASH Data
-
Intellia Therapeutics (NTLA) Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002
-
Form X-17A-5 FIRST ANALYSIS SECURITIE For: Dec 31
-
RenovoRx (RNXT) Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic
-
Castle Biosciences Inc. (CSTL) Presents New Data Demonstrating Impact of DecisionDx-SCC Test Results on Management of Medicare-Eligible Patients with cSCC and One or More Risk Factors
-
Intellia Therapeutics (NTLA) Reports Positive Interim Data for NTLA-2002
-
Mirum Pharmaceuticals (MIRM) Reports New Data at The International Liver Congress of the European Association for the Study of the Liver
-
Vertex Pharma (VRTX) to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at ECFS
-
TG Therapeutics (TGTX) Voluntarily Withdraws BLA/sNDA for U2 to Treat Patients with CLL and SLL
-
PureCycle Technologies (PCT) Appoints Steven F. Bouck and Allen Jacoby to its Board
-
Bristol-Myers Squibb (BMY), Nektar (NKTR) Announce Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo Did Not Meet Primary Endpoint
-
RedHill Biopharma (RDHL) Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19
-
PhaseBio Pharmaceuticals Inc. (PHAS) Reports Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab
-
Shockwave Medical (SWAV) Unveils First One-Year Results of Coronary Intravascular Lithotripsy
-
Hepion Pharmaceuticals (HEPA) Reports DSMB Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
-
BioMarin Pharma (BMRN) Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study
-
Pfizer (PFE), BioNTech (BNTX) COVID-19 Vaccine Shows Over 90% Efficacy in Phase 3 Study
-
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
-
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
-
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
-
Pfizer says no COVID-19 vaccine data yet, could be week or more before it reports
-
Baxter Supports New Study Showing Nutritional Needs in Critically Ill COVID-19 Patients and Published Practical Guidelines for Care
-
Baxter Supports New Study Showing Nutritional Needs in Critically Ill COVID-19 Patients and Published Practical Guidelines for Care
-
"COVID-19: The Greatest Cover Up In History - From Wuhan To The White House" Exposes Government Corruption & Malfeasance
-
observIQ Launches Powerful New Full Stack Log Management Platform to Beta
-
Pfizer vaccine trial bets on early win against coronavirus, documents show
-
How drugmakers can keep their pledge and still deliver an October vaccine surprise
-
Emergex and Bio-Manguinhos/Fiocruz Elucidate T Cell Epitopes Produced by Commercial Yellow Fever Vaccine
-
Mediant Announces $18.5 Million Equity Infusion To Support Next Phase Of Growth
-
William Blair Expands Equity Capital Markets Investment Banking Team, Adding Brian Friedman in Chicago
-
GenSight Biologics Reports Final REALITY Natural History Study Results Confirming Poor Spontaneous Recovery for LHON Patients With ND4 Mutation
-
Blue Medora Launches observIQ
-
Food commodities still at risk of coronavirus 'market shock' -FAO/OECD
-
Roche announces new data at the ISTH 2020 Congress, demonstrating ongoing commitment to advancing care for people with haemophilia A
-
Abbott (ABT) Announces New Late-Breaking Data Highlight Impact of its Minimally Invasive Structural Heart Therapies
-
New Late-Breaking Data Highlight Impact of Abbott's Minimally Invasive Structural Heart Therapies
-
New Data from the RECOVER™ Study Reveal Two-Year Outcomes in People with Opioid Use Disorder Following Transition from Pivotal Phase 3 Clinical Trials to a Real-World Setting
-
Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine
-
Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights
-
Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights
-
Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO
-
Genentech to Present First Clinical Data on Novel Anti-TIGIT Cancer Immunotherapy Tiragolumab at ASCO
-
sticky.io Announces Growth Equity Investment Following Recent Rebrand
-
Bayer to Highlight Clinical Data on Vitrakvi® (larotrectinib) and Research on Investigational AhR Inhibitor at AACR 2020 Virtual Meeting
-
VIDA Completes Second Close Of Round C Financing
-
Tabula Rasa HealthCare® Names Frank Sparacino SVP Investor Relations and Corporate Development
-
Tabula Rasa HealthCare® Names Frank Sparacino SVP Investor Relations and Corporate Development
-
Independent Third-Party Analyst Gives UC Asset “Buy” Rating with Target Price at $5.50 per Share
